Neoadjuvant Trastuzumab, Pertuzumab and Tucatinib Without Chemotherapy in HER2-positive Breast Cancer: the TRAIN-4 Study
Clinical trial NCT06162559 · RECRUITING
Trial details
- NCT number
- NCT06162559
- Sponsor
- The Netherlands Cancer Institute
- Status
- RECRUITING
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2023-12-18
- Primary completion
- 2026-08-01
- Enrollment
- 30
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.